The IDEA-FAST project is a 5-year IMI2 project under Call H2020-JTI-IMI2-2018-15-two-stage digital endpoints in neurodegenerative and immune-mediated diseases (total budget 42 Million) that starts in November 2019, run by a consortium of 46 partners across 15 countries in Europe. It received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853981.

This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.

IDEA-FAST aims to identify digital endpoints that provide reliable, objective and sensitive evaluation of activities of daily life (ADL), disability and health related-quality of life (HRQoL) for the following neurodegenrative diseases (NDD): Parkinson’s Disease (PD), Huntington’s Disease (HD) and the following immune-mediated inflammatory diseases (IMID): Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Primary Sjögren’s Syndrome (PSS), and Inflammatory Bowel Disease (IBD).